We are delighted to announce that Eagle IP has been recognized once more by IAM Patent 1000 - The World's Leading Patent Professionals - as a top ranked, “Highly Recommended Firm in Patent Prosecution”.

The IAM Patent 1000 is a respected annual directory dedicated to identifying leading patent firms and individual practitioners globally. Published by Intellectual Asset Management (IAM), the guide covers key jurisdictions and evaluates capabilities across the core areas of patent law. Inclusion in the directory is determined by a rigorous, independent research process that includes 900+ extensive interviews with in-house counsel, patent attorneys, and industry experts.

According to IAM, Eagle IP has carved out “a distinctive reputation for far-reaching and highly sophisticated patent protection” and “a prime pick for life sciences companies, research institutions and technology-driven enterprises navigating complex international patent strategies.”

IAM has further highlighted five individuals from our firm: Our President and Managing Director, Ms. Jennifer Che, Principal Ms. Yolanda Wang, Principal Ms. Pauli Wong, Dr. Jacqueline C Lui, Dr. Ho Chung Lui.

We are incredibly honoured to be included in this highest category among a select group of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US, Chinese, and Hong Kong patent laws, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

What Kind of Damage Awards Can You Get in China?

2022年6月16日
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
china-joins-two-wipo-treaties

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

2022年2月11日
It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger. We wanted to highlight a few new developments in China. China has joined the Hague System for the International Registration of Industrial Designs, submitting […]

No More Hindsight Bias: China’s Supreme People's Court Reins in Patent Inventiveness Assessments

2026年6月25日
For foreign applicants navigating patent litigation or invalidation in China, a common frustration is hindsight bias. Too often, CNIPA or lower courts strip down a patent into isolated technical features, find those features across disparate prior art references, and declare the invention to be "obvious". To counter such hindsight reasoning, the core criterion has always […]
Top crossarrow-right